regeneron

Regeneron injects $100 million and 300 new roles into Irish production facility

pharmafile | October 26, 2017 | News story | Manufacturing and Production Regeneron, Sanofi, manufacturing, pharma 

Sanofi subsidiary Regeneron has announced its intention to expand its production plant in Limerick, Ireland – the largest scale bulk biologic production facility in the country – adding 300 new roles and injecting $100 million to energise operations through increasing drug substance production capacity to meet rising demands.

This latest move in the region pushes Regeneron well beyond its past projections – in 2015, the company noted that it expected its operations at the Raheen Industrial Estate, where the facility is located, to reach 500 by the end of 2017. Instead, with this latest move the workforce is now expected hit 800 by the end of 2018. So far, the company has injected $750 million into the region since 2014.

“Gut feel is a large portion of any site selection. When we picked Limerick years ago, we simply felt good about the community, universities and people,” commented Dan Van Plew, Executive Vice President and General Manager of Industrial Operations and Product Supply at Regeneron. “A few years and a lot of experience later, I can now confidently say I know Limerick is a place where you can build and thrive as a biotech.

Advertisement

“We are proud of what has happened here and the vast majority of this work has been completed by people who come from Munster,” he continued. “These folks built, validated and began production in a way I’d put up against any other team on the planet. We feel at home here and the way we have been welcomed has made our ongoing growth and investment in Limerick rewarding on the most personal levels.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

BioDuro establishes joint manufacturing venture with Cenra

BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

The Gateway to Local Adoption Series

Latest content